MGI Pharma entered into three separate agreements in the field oncology. MGI Pharma acquired Zycos, which is focused on oncology and antivirals and Aesgen which is focused on treating side-effects associated with cancer treatment. Acquisition of Zycos would add ZYC101 that is in phase II clinical trials for treating cervical dysplasia and the acquisition of Aesgen would add Saforis™ (L-glutamine oral suspension) that is in phase III clinical trials for treating oral mucositis associated with cancer chemotherapy. MGI has also obtained the worldwide rights to Dacogen™ (decitabine) that is in phase III clinical trial for treating myelodysplastic syndromes from SuperGen. The analyst states that these three deals would provide good synergy for MGI and would greatly increase MGI’s revenues.